Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Bristol Meyers Squibb Company

Viiv Healthcare UK (no. 4) Limited

Viiv Healthcare UK Limited

Tao Wang

Zhongxing Zhang

John F Kadow

Nicholas A Meanwell

Zhiwei Yin

Paul Michael Scola

Kap-Sun Yeung

Yasutsugu Ueda

Li-Qiang Sun

Alicia Regueiro-Ren

Owen Brendan Wallace

Lawrence G Hamann

B Narasimhulu Naidu

Qiufen May Xue

Qian Zhao

Eric Mull

David J Carini

Edward H Ruediger

John A Bender

Clint A James

Jacob Swidorski

Timothy P Connolly

Ying Han

Nachimuthu Soundararajan

Shawn K Pack

Chung-Pin H Chen

David Kenneth Leahy

Dominique Thoraval

Pierre Sirard

Kathia Levesque

Daniel H Deon

Kyle E Parcella

Kyle J Eastman

Barry L Johnson

Annapurna Pendri

Manoj Patel

John D Matiskella

Samuel Gerritz

Zheng Liu

Guo Li

Weixu Zhai

David R Langley

Eric P Gillis

Carol Bachand

Bradley C Pearce

Haiquan Fang

Zhilei Qiu

Milind Deshpande

Piyasena Hewawasam

Mark George Saulnier

Jeffrey Lee Romine

Denis R St Laurent

Katharine A Grant-Young

Michael A Walker

Kevin M Peese

David Bertil Frennesson

Zhong Yang

Zhizhen Barbara Zheng

Wenying Li

Zhaoxing Meng

Juliang Zhu

Pin-Fang Lin

Wade S Blair

Timothy P Spicer

Hui Wang

Christopher Allard

Nicolas A Meanwell

Zhilei Qui

Alicia Regueiro-ren

In accordance with the present disclosure, compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

Immunomodulators

In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein:  Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein:

Salts of prodrugs of piperazine and substituted piperidine antiviral agents

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. 

5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV: 

Substituted benzofuran compounds for the treatment of hepatitis C

Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: 

Substituted 2-phenyl (AZA)benzofuran compounds for the treatment of hepatitis C

Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Macrocyclic benzofuran compounds for the treatment of hepatitis C

Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. In the compounds of formula (I), Ris selected from hydrogen, alkyl, or cycloalkyl; Ris selected from tetrahydroisoquinolinyl and is substituted with 1 Rsubstituent and also with 0-3 halo or alkyl substituents; Ris selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; Ris selected from alkyl or haloalkyl; Ris alkyl; Ris selected from Ar, (Ar)alkyl, (chromanyl)alkyl, cyanocycloalkyl or (dihydrobenzodioxinyl)alkyl; and Aris phenyl substituted with 0-5 substituents selected from cyano, halo, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, (hydroxy)alkoxy, (alkoxy)alkoxy, phenoxy, benzyloxy, carboxy, phenyl, and cyanocycloalkyl. 

Substituted pyridines as inhibitors of human immunodeficiency virus replication

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Compounds useful as immunomodulators

Compounds of Formula (I), including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. 

Benzofurans substituted with primary benzamide as HCV inhibitors

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus, (HCV) and may be useful in treating those infected with HCV. 

Benzofuran compounds for the treatment of hepatitis C

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV: Formula (I). 

Benzofurans substituted with bicyclic secondary benzamide as HCV inhibitors

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and areuseful in treating those infected with HCV. 

Benzofurans substituted with secondary benzamide as HCV inhibitors

Growing community of inventors

Farmington, CT, United States of America

Tao Wang